Effects and efficacy:
Clinically used for colon cancer, rectal cancer, gastric cancer, breast cancer, ovarian cancer, choriocarcinoma, malignant hydatidiform mole, head and neck squamous cell carcinoma, skin cancer, liver cancer, bladder cancer, etc.
Usage and dosage:
For patients with good hematopoietic function and nutritional status, the recommended dose is 12 mg/kg per day by intravenous injection, and the maximum daily dose is 800 mg. After 4 days of injection, if no toxicity is found, then change to 6 mg/kg dose, once every other day, for a total of 4 times. Intermittent for 4 weeks before starting the next course of treatment; and adjust the dose according to the efficacy and tolerance. Intravenous infusion: 15-30 mg/kg per day, slowly dripped within 6-8 hours, and used for 10 days as a course of treatment. Oral: 150-300 mg/d, taken in divided doses. The total amount is 10-15g for a course of treatment. For external use: 5% cream or 10%, 5% propylene glycol solution for rubbing.
Adverse reactions:
Nausea, loss of appetite or vomiting. Generally, the dose is not serious. Occasionally, oral mucosal inflammation or ulcers, abdominal discomfort or diarrhea are seen. Peripheral blood leukopenia is common (mostly reaches the lowest point within 2-3 weeks after the start of treatment and returns to normal after about 3-4 weeks).
Let us work together to protect precious health